Share
تاثير استخدام عقار الميتفورمين منفردا او مع عقار السيتاكلبتين على مستويات الاومنتين - 1 لدى مرضى داء السكري من النوع الثاني == Effects Of Metformin Alone Or In Combination With Sitagliptin On Serum Omentin - 1 Levels In Patients With Type - 2 Diabetes Mellitus
Author name:
ميقات طالب حمادة
Supervisor name:
حيدر مطير خليل القريشي | عبد الكريم يحيى السامرائي
General topic:
Medicine
Specific topic:
Medicines and Toxins
Degree:
Master
University:
Mustansiriyah University - Faculty Of Medicine - Pharmacology Department
Language:
English
University location:
Baghdad
First pages:
19T1185 - p.pdf
Abstract:
الخلفية : داء السكري يشير الى مجموعة من امراض الايض مع ارتفاع مستوى سكر الدم. يمثل النوع الثاني من داء السكري ما نسبته 90 - 95% من جميع حالات السكري. يمثل النقص في الانسولين ومقاومة الانسولين وغيرها من الاضطرابات الهرمونية المشاكل الاساسية لمرضى السكري من ال | Background : Diabetes mellitus (DM) describes chronic metabolic disorders with hyperglycemia. Type II DM (T2DM) represents for approximately 90 - 95% of all diabetic types. A combination of insulin deficiency, insulin resistance and other hormonal irregularities are key problems with T2DM. Adipose tissue can be classified into two types : the brown and white adipose tissues. The white type is considered an important secretory organ which produces many bioactive molecules, collectively termed adipokines. Recently, a new adipokine named omentin - 1, has been identified and it was found that individuals with impairment in glucose homeostasis and newly diagnosed T2DM showed a lower serum omentin - 1 level. However, the effects of antidiabetes drugs on serum omentin - 1 level had not been studied extensively.Objective : The current study was design to measure serum omentin - 1 in T2DM as comparing with control subjects, also to study the effect of three months therapy with metformin and/or sitagliptin (when added to ongoing metformin therapy) on serum omentin - 1 levels in addition to other parameters.Method : This study was carried out on thirty healthy control subjects, and sixty three T2DM patients. The patients enrolled in the current study were divided into two groups. First group : included thirty one of newly diagnosed T2DM patients, started treatment with metformin. Second group : included thirty two patients with T2DM, already on ongoing metformin therapy and started treatment with sitagliptin. All patients received their treatment for three months duration, and blood samples were collected from them at the beginning of the study and after three months of starting treatment to measure the possible change in the studied parameters which include : fasting blood glucose (FBG), postprandial blood glucose (PBG), Glycosylated haemoglobin (HbA1c), serum level of insulin, insulin resistance (IR), serum omentin - 1 levels, lipid profile, body mass index (BMI) as well as blood pressure. Results : The results showed that baseline level of serum omentin - 1 in the newly diagnosed T2DM was significantly lower than matched control subjects. The level of omentin - 1 was significantly reduced after three months duration of treatment in sitagliptin group with no significant change in metformin group. FBG, HbA1c and PBG were decreased significantly after three months in metformin group, while in sitagliptin group, only HbA1c and PBG were decreased significantly after three months. In both groups, and after three months duration of treatment, there were no significant changes in serum level of insulin, IR, TG, VLDL - C, HDL - C, BMI, and blood pressure.Conclusion : In newly diagnosed patients with T2DM, serum omentin - 1 was reduced compared to age and BMI matched healthy subjects. Three months treatment with sitagliptin resulted in a significant reduction in omentin - 1 levels compared with baseline values. However, three months treatment with metformin had no significant effect on serum omentin - 1 level compared with pre - treatment value
